Every material Form 8-K Scholar Rock Holding Corp has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Scholar Rock disclosed that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years and older receiving an SMN2-targeted treatment. The company also corrected management's statement during the September 14, 2026 investor call that the FDA required no post-marketing safety commitments, saying the FDA does require a pregnancy safety study and fracture alert reports.
FDA approved ISEMBYLD for SMA patients aged 2 and older currently on an SMN2-targeted treatment
FDA requires a post-marketing pregnancy safety study covering pregnancy complications and birth outcomes
FDA requested that all serious and non-serious fracture cases be submitted as 15-day alert reports
Correction was made to statements made in error during the September 14, 2026 investor call
On September 11, 2026, Scholar Rock Holding Corporation announced that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years of age and older who are receiving an SMN2-targeted treatment. The company said the U.S. commercial launch is underway, with product available to ship in the coming days, and it received a Rare Pediatric Disease Priority Review Voucher with the approval.
Phase 3 SAPPHIRE study: 2.2-point HFMSE motor function improvement vs. placebo at one year (nominal p=0.0121)
34.2% of ISEMBYLD-treated patients showed a 3-point or greater HFMSE increase vs. 13.5% on placebo
Fractures occurred in 9% of ISEMBYLD 10 mg/kg patients vs. 2% on placebo; the label notes an increased fracture risk
Management webcast and conference call on September 14, 2026, at 8:00 a.m. ET; cash and securities were $492 million as of June 30, 2026
Scholar Rock Holding Corporation filed a prospectus supplement for an at-the-market offering that lets it sell up to $200 million of common stock through Jefferies as sales agent, at its discretion. The filing replaces the prior supplement dated November 14, 2025, whose offering has been terminated, and the company says it has raised about $257.7 million in net proceeds under the ATM Program to date. New share sales would add to existing shareholders' ownership and could dilute their stake.
Up to $200,000,000 in additional common stock may be sold through Jefferies, filed August 6, 2026
Replaces the prospectus supplement dated November 14, 2025, which has been terminated
About $257.7 million in net proceeds raised under the ATM Program to date
Shares are registered under a Form S-3ASR shelf filed October 7, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Scholar Rock Holding Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →